Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05702034 · ClinicalTrials.gov registry record · Phase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
A Phase 3 study of Ischemic Stroke; Ischemic Attack, Transient, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15,000
- Enrollment target
- 20
- Study locations
NCT05702034 is a Phase 3 study of Ischemic Stroke; Ischemic Attack, Transient that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 15,000 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT05702034, a Phase 3 study of Ischemic Stroke; Ischemic Attack, Transient, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Milvexian
Study Locations (20)
California
- Alta Bates Medical Center Cancer Center - Berkeley
- Providence Saint Joseph Medical Center - Cancer Center - Burbank
- Mills Peninsula Health Services - Burlingame
- Sutter Health - Eden Medical Center - Castro Valley
- Neurology Center of North Orange County - Fullerton
- Glendale Adventist Medical Center - Glendale
- UC Irvine Healthcare Center - Irvine
- Sharp Grossmont Hospital - La Mesa
- Long Beach Memorial - Long Beach
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Mission Hospital Regional Medical Center - Mission Viejo
- Hoag Memorial Hospital - Newport Beach
- Stanford Stroke Center - Palo Alto
- Kaiser Permanente - Redwood City
- University of California Davis Health System - Sacramento
- Kaiser Permanente - Sacramento
- California Pacific Medical Center - San Francisco
Arizona
- Banner Desert Medical Center - Mesa
- University of Arizona - Tucson
Arkansas
- Plaza Neuroscience Clinic - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2026-12-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05702034
The ClinicalTrials.gov registry entry for NCT05702034 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 15,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemic Stroke; Ischemic Attack, Transient appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05702034 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05702034 about?
NCT05702034 is a clinical study titled "A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE". The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
What is the current status of trial NCT05702034?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15,000 participants. The study started on 2023-02-15. Estimated completion is 2026-12-09.
What conditions does trial NCT05702034 study?
This clinical trial studies the following conditions: Ischemic Stroke; Ischemic Attack, Transient.
What interventions are being tested in trial NCT05702034?
The interventions under investigation include: Placebo (DRUG), Milvexian (DRUG).
Who is sponsoring clinical trial NCT05702034?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05702034 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.